CD274 and neoplasm: Recent phase I studies using antibodies that target PD-L1 (atezolizumab) in women with metastatic TNBC have demonstrated that a minority of women (<10%) exhibit tumor response.19,20 These studies prompted us to use TNBC as one of the models to study PD-L1 function in tumor.